

---

PRESS RELEASE

19 January 2021

## SyntheticMR's MSK package receives CE-mark in Europe

**SyntheticMR announced today that their quantitative imaging software solution SyMRI® has received a CE-mark for its product package SyMRI MSK, which can now be marketed and sold in Europe.**

The SyMRI MSK product package provides a fast scan that can help improve patient throughput, produce a range of contrast-weighted images, as well as quantitative T1, T2, and PD maps for both clinical and research practices for all MSK anatomies and joints – including spine. Quantitative imaging has shown a lot of potential within MSK applications, particularly for improved cartilage assessment.

"Europe is one of our key markets, and we look forward to introducing our MSK applications in this region," said Ulrik Harrysson, CEO, SyntheticMR. "Quantitative imaging has a clear role in MSK and spine imaging. We look forward to bringing this technology to new customer groups as well as to current users of our product package SyMRI NEURO, to help support more informed decisions and improved radiology workflows."

SyMRI uses a unique scanning sequence to measure the absolute properties of the anatomy. The product package SyMRI MSK joins SyntheticMR's growing portfolio of quantitative software solutions, which also includes SyMRI NEURO.

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 [ulrik.harrysson@syntheticmr.com](mailto:ulrik.harrysson@syntheticmr.com).

###

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single fast scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for MSK anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared, SyMRI MSK is CE-marked and FDA 510(k) pending. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden.

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 [ulrik.harrysson@syntheticmr.com](mailto:ulrik.harrysson@syntheticmr.com).

*This information is information that SyntheticMR AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 19 January 2021.*